Latest Breaking News On - Akeso inc - Page 1 : comparemela.com

CTLA-4 Inhibitors Pipeline Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Mechanism Of Action, Route Of Administration, And Comp...

United-states
Innovent-biologics
Bristol-myers-squibb
Akeso-biopharma
Drugs-under-different-phases-of-clinical-development
Pharmaceuticals-inc
Drug-administration
University-collaborations-licensing-partnering-analysis
Alpine-immune-sciences
Akeso-biopharma-co-ltd
Route-of-administration
Astrazeneca

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
thailand-business-news.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thailand-business-news.com Daily Mail and Mail on Sunday newspapers.

China
France
Li-zhang
Zhejiang
Italy
United-states
Japan
Germany
Thailand
United-kingdom
Canada
Chicago

Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA

Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Canada
Florida
United-states
Italy
China
California
France
Germany
Japan
Spain
Australia
Miami

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy | Taiwan News

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy | Taiwan News
taiwannews.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from taiwannews.com.tw Daily Mail and Mail on Sunday newspapers.

China
Chicago
Illinois
United-states
United-kingdom
Japan
Canada
Italy
Germany
Li-zhang
Zhejiang
France

Akeso's Ivonescimab Outperforms in Clinical Trial

Akeso, Inc. (HK:9926) has released an update. Akeso, Inc. has announced that its bi-specific antibody, ivonescimab, showed superior efficacy compar.

Akeso-inc